What is the optimal time to retest patients with a urogenital chlamydia infection?
ISRCTN | ISRCTN12159453 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN12159453 |
- Submission date
- 01/05/2017
- Registration date
- 09/05/2017
- Last edited
- 14/11/2017
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Plain English summary of protocol
Background and study aims
Chlamydia is a common sexually transmitted infection. The current guidelines recommend testing again after a chlamydia infection, but the best timing is not known. The aim of this study is to find the best time to retest after chlamydia treatment.
Who can participate?
Heterosexual patients of the Amsterdam STI clinic with a chlamydia infection, aged 12 or older
What does the study involve?
After being diagnosed and treated, participants are randomly allocated to be offered a retest either 8, 16 or 26 weeks later. Participants can choose to do this at home and send a self-collected sample by mail, or at the clinic. The number and percentage of participants retested and chlamydia infection rates are assessed up to 35 weeks later.
What are the possible benefits and risks of participating?
The benefit for the participant is that chlamydia re-infections are diagnosed and treated. There are no risks involved in participation.
Where is the study run from?
Public Health Service (GGD) Amsterdam (Netherlands)
When is the study starting and how long is it expected to run for?
May 2012 to April 2017
Who is funding the study?
Public Health Service (GGD) Amsterdam (Netherlands)
Who is the main contact?
Prof. Henry de Vries
Contact information
Scientific
Public Health Service
Department of Infectious Diseases
Nieuwe Achtergracht 100
Amsterdam
1018WT
Netherlands
0000-0001-9784-547X |
Study information
Study design | Single-centre randomized controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Other |
Study type | Screening |
Participant information sheet | No participant information sheet available |
Scientific title | What is the optimal time to retest patients with a urogenital chlamydia infection? A randomized controlled trial |
Study objectives | The trialists postulated that in heterosexual visitors of the STI clinic with a urogenital chlamydia infection, the proportion being retested would be lower with a later timing of retest, and that the proportion positive would be higher with a later timing of retest. If so, the trialists envisioned an optimum timing to offer a retest, which would provide the highest yield of diagnosed reinfections. |
Ethics approval(s) | The study was reviewed by the ethics committee of the Academic Medical Center, University of Amsterdam, Netherlands. The board exempted the study from a full review and written patient consent as it was a modification of current practice and did not apply to the Dutch law ‘Medical Research Involving Human Subjects Act (WMO)’. |
Health condition(s) or problem(s) studied | Urogenital Chlamydia trachomatis infection |
Intervention | A single-centre randomized controlled trial among urogenital chlamydia nucleic acid amplification test positive heterosexual Amsterdam STI clinic clients. After treatment, patients were randomly assigned for retesting 8, 16 or 26 weeks later. Patients could choose to do this at home (and send a self-collected sample by mail), or at the clinic. Retest uptake and chlamydia positivity at follow-up were calculated. |
Intervention type | Other |
Primary outcome measure | 1. The number and percentage of participants retested up to 35 weeks after inclusion 2. The proportion of participants who were CT positive, measured by nucleic acid amplification test, up to 35 weeks after inclusion |
Secondary outcome measures | 1. The number, percentage and chlamydia positivity proportion of participants who: 1.1. Returned more than 1 week before the assigned date 1.2. Returned at assigned date (this was defined as a visit in the period >1 week before, until 6 weeks after the assigned date) 1.3. Returned >6 weeks after the assigned date but no later than 35 weeks (8 months) after inclusion 1.4. Those who did not return within 35 weeks of inclusion |
Overall study start date | 01/05/2012 |
Completion date | 01/04/2017 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Mixed |
Sex | Both |
Target number of participants | 2500 |
Key inclusion criteria | 1. Heterosexual patients of the Amsterdam STI clinic testing positive for urogenital chlamydia 2. Aged 12 years or older |
Key exclusion criteria | Does not meet inclusion criteria |
Date of first enrolment | 01/05/2012 |
Date of final enrolment | 01/03/2013 |
Locations
Countries of recruitment
- Netherlands
Study participating centre
Department of Infectious Diseases
Weesperplein 1
Amsterdam
1018 WT
Netherlands
Sponsor information
Government
Department of Infectious Diseases
Nieuwe Achtergracht 100
Amsterdam
1018 WT
Netherlands
Website | ggd.amsterdam.nl |
---|---|
https://ror.org/042jn4x95 |
Funders
Funder type
Government
No information available
Results and Publications
Intention to publish date | 15/05/2017 |
---|---|
Individual participant data (IPD) Intention to share | Yes |
IPD sharing plan summary | Available on request |
Publication and dissemination plan | The trialists have presented the preliminary results during two scientific meetings, in 2013 during the international society for STD Research (ISSTDR) meeting in Vienna, Austria, and in 2014 during the International Society for Human Chlamydia Infection (ISHCI) meeting in Monterrey, CA, USA. Currently they are submitting the definite results to a scientific peer reviewed journal. |
IPD sharing plan | The datasets generated during and/or analysed during the current study are/will be available upon request from Prof. Henry de Vries. |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 01/02/2018 | Yes | No |
Editorial Notes
14/11/2017: Publication reference added.